SCHEMBL287312

SCHEMBL287312

O=C(CN1C=CC(C(=O)NNS(=O)(=O)c2ccccc2)C=C1)Nc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
BCAT1 P54687 1/20 0.42
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KAT6A Q92794 3/20 0.41
HTT P42858 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287496 0.73 KAT6A (0.44) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL659675 0.70 NPSR1 (0.44) ALDH1A1TSHRTDP1HTTHPGD
SCHEMBL28696236 0.69 CA12 (0.77) ALDH1A1CA12CA1CA2CA9
SCHEMBL27473204 0.69 CHRNB2 (0.46) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL27511902 0.69 KAT6A (0.43) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL287681 0.68 ALDH1A1 (0.55) ALDH1A1TSHRTDP1HTTHPGD
SCHEMBL6224735 0.67 KAT6A (0.59) KAT6AHTTMEN1KMT2AGAA
Hydrochloric Acid SCHEMBL1194104 0.66 KAT6A (0.58) BCAT1KAT6AHTTMEN1KMT2A
SCHEMBL3072716 0.65 ALDH1A1 (0.80) ALDH1A1CA12CA1CA2CA9
SCHEMBL7644248 0.64 BCAT1 (0.67) CA12CA1CA2CA9BCAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT CHRNB2 3557/4885CHRNB4 3101/4885CHRNA3 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.